logo
Plus   Neg
Share
Email

Stock Alert: Sorrento Therapeutics Down 10%

Shares of Sorrento Therapeutics, Inc. (SRNE) are currently losing nearly 10% on Monday morning following the news that Yale's saliva-based COVID-19 test received emergency use authorization from FDA, while SRNE's saliva-based test is still in development.

SRNE is currently trading at $11.20, down $1.23 or 9.93%, on the Nasdaq.

Sorrento's stock took a hit as the biotech company too has a saliva-based COVID-19 test in development. Last month, Sorrento announced it has entered into a licensing agreement with Columbia University for the rights to a rapid, one-step diagnostic test that detects SARS-CoV-2 virus in as little as 30 minutes from a sample of saliva.

Meanwhile, Yale's competing saliva-based COVID-19 test is reported to be given away for free.

The testing method is immediately available to other diagnostic laboratories that want to start using the new test, which can be scaled up quickly for use across the nation, the researchers said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Union and Britain have cleared Boeing's 737 Max for return to service in their respective regions after being grounded for nearly two years. The EU's air safety watchdog European Union Aviation Safety Agency or EASA in a statement said the agency has approved the return to service of a modified version of the Boeing 737 MAX. The UK Civil Aviation Authority or CAA also lifted the ban. Euromarket Designs, Inc., doing business as CB2, has recalled Junction tall chests and low dressers citing tip-over and entrapment hazards to children, according to the U.S. Consumer Product Safety Commission. The Chicago, Illinois - based company has called back about 11,000 units sold in the United States and about 355 units sold in Canada. Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) reported a profit for the fourth-quarter that increased 23.3 percent from last year, led by display and memory chip businesses.Quarterly revenue grew 2.8 percent from the prior year. The company expects overall profit to weaken in the first quarter of 2021.
Follow RTT